ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 2 filers reported holding ARRAY BIOPHARMA INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $1,267,000 | +6.2% | 27,357 | -44.1% | 0.27% | -89.5% |
| Q1 2019 | $1,193,000 | +117.7% | 48,922 | +27.1% | 2.54% | +2600.0% |
| Q4 2018 | $548,000 | +37.0% | 38,479 | +46.4% | 0.09% | +129.3% |
| Q3 2018 | $400,000 | -47.2% | 26,284 | -41.7% | 0.04% | -93.9% |
| Q2 2018 | $757,000 | -32.5% | 45,087 | -34.4% | 0.67% | -31.3% |
| Q1 2018 | $1,122,000 | +173.0% | 68,763 | +114.1% | 0.97% | +88.8% |
| Q4 2017 | $411,000 | -21.0% | 32,118 | -24.0% | 0.52% | +637.1% |
| Q3 2017 | $520,000 | +62.0% | 42,236 | +10.1% | 0.07% | +45.8% |
| Q2 2017 | $321,000 | +12.2% | 38,373 | +19.8% | 0.05% | -5.9% |
| Q1 2017 | $286,000 | +12.6% | 32,023 | +10.6% | 0.05% | -32.9% |
| Q4 2016 | $254,000 | -49.9% | 28,953 | -61.4% | 0.08% | -69.0% |
| Q3 2016 | $507,000 | +89.9% | 75,100 | 0.0% | 0.24% | +23.7% |
| Q2 2016 | $267,000 | +36.2% | 75,100 | +13.1% | 0.20% | -26.7% |
| Q1 2016 | $196,000 | – | 66,376 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Redmile Group, LLC | 16,618,776 | $146,079,000 | 12.59% |
| BVF INC/IL | 4,986,186 | $43,829,000 | 8.81% |
| First Light Asset Management, LLC | 1,000,361 | $8,793,000 | 3.86% |
| Crosspoint Capital Strategies, LLC | 463,005 | $4,070,000 | 3.62% |
| Consonance Capital Management LP | 2,723,471 | $23,912,000 | 2.63% |
| KOPP INVESTMENT ADVISORS LLC | 219,926 | $1,933,000 | 2.04% |
| SPHERA FUNDS MANAGEMENT LTD. | 900,000 | $7,911,000 | 2.00% |
| Orbimed Advisors | 16,088,800 | $141,421,000 | 1.80% |
| Cormorant Asset Management, LP | 1,150,000 | $10,109,000 | 1.36% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 2,073,680 | $18,227,000 | 1.26% |